联系方式
Contact Information
团队简介
Team Introduction
以黄鹤教授领衔的生物医药工程实验室科研团队依托于天津大学化工学院和系统生物工程教育部重点实验室,课题组长期专注于生物医药工程研究领域,始终倡导将前沿性基础研究成果与国民经济发展和国家重大需求紧密相连,目前主要研究方向有:开展药物合成生物学研究,包含:针对不同类型活性成分改造高适配性底盘细胞、以及功能生物大分子的理性设计和高效制备;极端环境微生物基因元件挖掘、肠道微生态平衡与人体健康、耐药致病微生物代谢机理与应对策略;高值医药及生化产品的微生物育种及发酵法生产等。
多年来,课题组主持承担或参加国家科技重大专项“理性设计应用于门冬胰岛素生产工具酶的热稳定性提高”、“生物药大品种的技术升级”、国家自然科学基金项目“抗HIF-1α纳米抗体靶向治疗胰腺癌的实验研究”、“工业生物技术的过程科学基础研究”、“肠道微生态关键技术研究”等省部级以上项目10余项,目前主要承担国家重点研发计划“合成生物学”重点专项“合成生物肠道菌群体系构建及应用”,通过大数据挖掘功能元件,创新设计了丁酸、丙酸等短链脂肪酸异源微生物细胞工厂;首次提出了表征炎性肠病微生物组空间群落结构的 X-Y-Z-三维模型;首次预测并验证了蓝杆菌51142复制起始元件;首次解析了多重耐药鲍曼不动杆菌MDR-TJ全基因组信息,并针对其耐药模块开发生物解决方案。课题组近期获中国药学会科技进步奖一等奖1项,北京市科技进步二等奖1项,在Cell、Nature Microbiology、Nature Communications、Biotechnology Advances、Acta Pharmaceutica Sinica B、Gut Microbes、Cancer Letters等高水平期刊发表论文百余篇,出版著作3部,获授权发明专利二十余项。
将合成生物学技术应用于药物研发的产业化场景,在全球范围内属前沿学科及新兴领域。团队目前围绕合成生物学技术进行活菌药物开发的技术平台处于国际先进水平。在黄鹤教授指导下,课题组秉持严谨活泼、求真务实的发展理念,坚持研究生素质全面培养,综合发展。科学研究方面,坚持实事求是、以德为先,在增强自身科学文化素养的同时,注重培养学生创新实践能力。学术交流方面,课题组与英国格拉斯哥大学、斯洛文尼亚新戈里察大学、马来西亚拉曼大学、北京大学、清华大学、青岛医科大学、温州医科大学等国内外高校共同承担研究项目,学生交流合作频繁。团队建设方面,积极开展丰富多样的团建活动,增强团队凝聚力;定期开展组会交流讨论活动,拓展前沿视野,夯实专业基础;组织体育锻炼活动,强健身心;建立传帮带制度,增强团队核心战斗力。
2022年新华网采访视频
课题组核心成员
主持参加国家重点研发计划“合成生物学”重点专项项目、国家科技重大专项、国家自然科学基金等。
l 国家重点研发计划“合成生物学”重点专项,合成生物肠道菌群体系构建及其应用;
l 国家自然科学基金,抗HIF-1α纳米抗体靶向治疗胰腺癌的实验研究;
l 天津市重点研发计划,TNF-α/IL-23双特异性纳米抗体靶向治疗炎症性肠病的实验研究;
l 天津市重点研发计划,断奶仔猪用高活性益生菌制剂的研发与应用研究
l 山东省重大基础研究项目,类调节T细胞参与肿瘤免疫逃逸的分子机制及靶向干预策略;
l 天津市自然科学基金,多特异性纳米抗体体外亲和力成熟平台的设计、构建和优化。
实验室
公共平台
近年代表性论文:
2024
[1] Kang G., Wang X., Gao M., WangL., Feng Z., Meng S., Wu J., Zhu Z., Gao X., Cao X., Huang H. Propionate-producing engineered probiotics ameliorated murine ulcerative colitis by restoring anti-inflammatory macrophage via the GPR43/HDAC1/IL-10 axis[J]. Bioengineering & Translational Medicine, 2024: 10.1002/btm2.10682.
[2] Liu Y., Wong C., Ding Y., Gao M., Wen J., Lau H., Cheung A., Huang D., Huang H., Yu J. Peptostreptococcus anaerobius mediates anti-PD1 therapy resistance and exacerbates colorectal cancer via myeloid-derived suppressor cells in mice[J]. Nature Microbiology, 2024: 10.1038/s41564-024-01695-w.
[3] Chen X., Gao M., Wang L., Qiang G., Wu Y., Huang H., Kang G. A synthetic microbial consortium protects against obesity by regulating vitamin B6 metabolism[J]. Gut Microbes, 2024, 16(1): 2304901.
[4]Fu K., Cheung A., Wong C., Liu W., Zhou Y., Wang F., Huang P., Yuan K., Coker O., Pan Y., Chen D., Lam N., Gao M., Zhang X., Huang H., To K., Sung J., Yu J. Streptococcus anginosus promotes gastric inflammation, atrophy, and tumorigenesis in mice[J]. Cell, 2024, 187: 1-15.
[5] Wu J., Huang H., Wang L., Gao M., Meng S., Zou S., Feng Y., Feng Z., Zhu Z., Cao X., Li B., Kang G. A tailored series of engineered yeasts for the cell-dependent treatment of inflammatory bowel disease by rational butyrate supplementation[J]. Gut Microbes, 2024, 16(1): 2316575.
[6] Gong Z., Kang G., Shi R., Jiang X., Rong X., Du X., Wu J., Huang H., Meng S. Intermolecular interaction between BODIPY and TPE enhances phototherapy[J]. Adv. Optical Mater., 2024, 2303033.
[7]Wang J., Kang G., Lu H., Marco A., Yuan H., Feng Z., Gao M., Wang X., Wang H., Zhang X., Wang Y., Zhang M., Wang P., Feng Y., Liu Z., Cao X., Huang H. Novel bispecific nanobody mitigates experimental intestinal inflammation in mice by targeting THF-α and IL-23p19 bioactivities[J]. Clin. Transl. Med., 2024, 14: e1636.
2023
[1] Du K., Huang H. Development of anti-PD-L1 antibody based on structure prediction of AlphaFold2[J]. Frontiers in Immunology, 2023, 14: 1275999.
[2] Li J., Kang G., Wang J., Yuan H., Wu Y., Meng S., Wang P., Zhang M., Wang Y., Feng Y., Huang H., Marco A. Affinity maturation of antibody fragments: A review encompassing the development from random approaches to computational rational optimization[J]. International Journal of Biological Macromolecules, 2023, 247: 125733.
[3] Du J., Zhang J., Wang L., Wang X., Zhao Y., Lu J., Fan T., Niu M., Zhang J., Cheng F., Jun L., Zhu Q., Zhang D., Pei H., Li G., Liang X., Huang H., Cao X., Liu X., Shao W., Sheng J. Selective oxidative protection leads to tissue topological changes orchestrated by macrophage during ulcerative colitis[J]. Nature Communications, 2023, 14: 3675.
[4] Li X., Song Y., Chen X., Yin J., Wang P., Huang H., Yin H. Single-cell microfluidics enabled dynamic evaluation of drug combinations on antibiotic resistance bacteria[J]. Talanta, 2023, 265(6): 124814.
[5] Dang Z., Gao M., Wang L., Wu J., Guo Y., Zhu Z., Huang H., Kang G. Synthetic bacterial therapies for intestinal diseases based on quorum- sensing circuits[J]. Biotechnology Advances, 2023, 65: 108142.
[6] Feng Z., Kang G., Wang J., Gao X., Wang X., Ye Y., Liu L., Zhao J., Liu X., Huang H., Cao X. Breaking through the therapeutic ceiling of inflammatory bowel disease: Dual-targeted therapies[J]. Biomedicine & Pharmacotherapy, 2023, 158(8): 114174.
[7] Huang H., Yin H., Zhang X. Editorial: Engineering probiotics for multiple interventions on intestinal diseases[J]. Frontiers in Cellular and Infection Microbiology, 2023, 13: 1138998.
2022
[1] Bai Z., Wang J., Li J., Yuan H., Wang P., Zhang M., Feng Y., Cao X., Cao X., Kang G., Marco A., Huang H. Design of Nanobody-based Bispecific Constructs by in silico Affinity Maturation and Umbrella Sampling Simulations[J]. Computational and Structural Biotechnology Journal, 2022, 21: 12.021.
[2] Yang W., Zhao Y., Ge Q., Wang X., Jing Y., Zhao J., Liu G., Huang H., Cheng F., Wang X., Ye Y., Song W., Lu X., Du J., Sheng J., Cao X. Genetic mutation and tumor microbiota determine heterogenicity of tumor immune signature: Evidence from gastric and colorectal synchronous cancers[J]. Frontiers in Immunology, 2022, 13: 947080.
[3] Cao X., Dong A., Kang G., Wang X., Duan L., Hou H., Zhao T., Wu S., Liu X., Huang H., Wu R. Modeling spatial interaction networks of the gut microbiota[J]. Gut Microbes,2022, 14(1).
[4] Cao X., Yuan H., Liang J., Huang H. Elective Switching on Biosimilars: Far More Than Nonmedical Switching[J]. Inflammatory Bowel Diseases, 2022, 28(7): E101-E102.
[5] Lin Y., Jiang X., Liu Y., Wang N., Shi R., Wang Y., Feng Y., Huang H., Meng S.X. A new nanohybrid with BODIPY and Fe3O4 modified graphdiyne oxide in theranostic[J]. 2d Materials, 2022, 9(4).
[6] Wang J., Kang G., Yuan H., Cao X., Huang H., De Marco A. Research Progress and Applications of Multivalent, Multi-specific and Modified Nanobodies for Disease Treatment[J]. Frontiers in Immunology, 2022, 12.
[7] Wang L., Cheng X., Bai L., Gao M., Kang G., Cao X., Huang H. Positive Interventional Effect of Engineered Butyrate-Producing Bacteria on Metabolic Disorders and Intestinal Flora Disruption in Obese Mice[J].Microbiology Spectrum, 2022, 10(2).
[8] Wang X., Feng Z., Ye Y., Huang H., Cao X., Zhao J. Tu1482:Propionate ameliorates intestinal inflammation through M2A macrophage polarization and promotes the production of IL-10 [J]. Gastroenterology, 2022,162(7): S980-S980.
[9] Yin J., Chen X., Li X., Kang G., Wang P., Song Y., Ijaz U., Yin H., Huang H. A droplet-based microfluidic approach to isolating functional bacteria from gut microbiota[J]. Frontiers in Cellular and Infection Microbiology, 2022,12.
2021
[1] Hu Y., Kang G., Wang L., Gao M., Wang P., Yang D., Huang H. Current Status of Mining, Modification, and Application of Cellulases in Bioactive Substance Extraction[J]. Current Issues in Molecular Biology, 2021, 43(2):687-703.
[2] Li X., Song Y., Wang L., Kang G., Wang P., Yin H., Huang H. A Potential Combination Therapy of Berberine Hydrochloride With Antibiotics Against Multidrug-Resistant Acinetobacter baumannii[J]. Frontiers in Cellular and Infection Microbiology, 2021, 11.
[3] Soler M., Medagli B., Wang J., Oloketuyi S., Bajc G., Huang H., Fortuna S., De Marco A. Effect of Humanizing Mutations on the Stability of the Llama Single-Domain Variable Region[J]. Biomolecules, 2021, 11(2).
[4] Wang L., Gao M., Kang G., Huang H. The Potential Role of Phytonutrients Flavonoids Influencing Gut Microbiota in the Prophylaxis and Treatment of Inflammatory Bowel Disease[J]. Frontiers in Nutrition, 2021, 8.
[5] Wang Y., Zhang X., Wang Y., Zhao W., Li H., Zhang L., Li X., Zhang T., Zhang H., Huang H., Liu C. Application of immune checkpoint targets in the anti-tumor novel drugs and traditional Chinese medicine development[J]. Acta Pharmaceutica Sinica B, 2021, 11(10): 2957-2972.
[6] Kang G., Hu M., Ren H., Wang J., Cheng X., Li R., Yuan B., Balan Y., Bai Z., Huang H. VHH212 nanobody targeting the hypoxia-inducible factor 1α suppresses angiogenesis and potentiates gemcitabine therapy in pancreatic cancer in vivo[J]. Cancer Biology & Medicine, 2021,18(3): 772-787.
2020
[1] Bai L., Gao M., Cheng X., Kang G., Cao X., Huang H. Engineered butyrate-producing bacteria prevents high fat diet-induced obesity in mice[J].Microbial Cell Factories, 2020, 19(1).
[2] Bai L., Zhang S., Deng Y., Song C., Kang G., Dong Y., Wang Y., GaoF., Huang H. Comparative genomics analysis of Acinetobacter haemolyticus isolates from sputum samples of respiratory patients[J]. Genomics, 2020,112(4): 2784-2793.
[3] Xu J., Li X., Kang G., Bai L., Wang P., Huang H. Isolation and Characterization of AbTJ, an Acinetobacter baumannii Phage, and Functional Identification of Its Receptor-Binding Modules[J]. Viruses-Basel, 2020, 12(2).
[4] Hu M., Kang G., Cheng X., Wang J., Li R., Bai Z., Yang D., Huang H. In vitro affinity maturation to improve the efficacy of a hypoxia-inducible factor 1α single-domain intrabody[J]. Biochemical and Biophysical Research Communications, 2020, 529(4): 936-942.
[5] Kang G., Wang J., Cao X., Huang H. Simultaneous targeting of TNF-alpha and IL-23 with a novel bispecific nanobody for the therapy of ulcerative colitis[J]. Basic & Clinical Pharmacology& Toxicology, 2020, 126(3):178-178.
2019
[1] Cheng X., Wang J., Kang G., Hu M., Yuan B., Zhang Y., Huang H. Homology Modeling-Based in Silico Affinity Maturation Improves the Affinity of a Nanobody[J]. International Journal of Molecular Sciences, 2019, 20(17).
[2] Li R., Kang G., Hu M., Huang H. Ribosome Display: A Potent Display Technology used for Selecting and Evolving Specific Binders with Desired Properties[J]. Molecular Biotechnology, 2019, 61(1): 60-71.
[3] Wang Y., Cui T., Li Y., Liao M., Zhang H., Hou W., Zhang T., Liu L., Huang H., Liu C. Prediction of quality markers of traditional Chinese medicines based on network pharmacology[J]. Chinese Herbal Medicines, 2019, 11(4):349-356.
2018
[1] Li T., Kang G., Wang T., Huang H. Tumor angiogenesis and anti-angiogenic gene therapy for cancer (Review)[J]. Oncology Letters, 2018,16(1): 687-702.
[2] Liu L., Yu H., Du K., Wang Z., Gan Y., Huang H. Enhanced trypsin thermostability in Pichia pastoris through truncating the flexible region[J].Microbial Cell Factories, 2018, 17.
[3] Liu Y., Huang H. Expression of single-domain antibody in different systems[J]. Applied Microbiology and Biotechnology, 2018, 102(2): 539-551.
[4] Wang Z., Guo C., Liu L., Huang H. Effects of N-glycosylation on the biochemical properties of recombinant bEK(L) expressed in Pichia pastoris[J].Enzyme and Microbial Technology, 2018, 114: 40-47.
[5] Xie K., Deng Y., Zhang X., Wang X., Kang G., Bai L., Huang H. Biases in Prokaryotic Community Amplicon Sequencing Affected by DNA Extraction Methods in Both Saline and Non-saline Soil[J]. Frontiers in Microbiology, 2018, 9.
第一发明人授权专利:
CN114957467A特异性结合TNF-α的纳米抗体及其用途
CN114920839A特异性结合IL-23的纳米抗体及其用途
CN114669337A一种微流控装置及其在分离细菌中的应用
ZL202010868371. 7一种联合抗菌药物组合物及其应用
CN114525214B一种工程益生菌的构建方法及其应用
ZL202010069798.0一种多重耐药鲍曼不动杆菌识别元件的挖掘与验证
CN112126615B一种产丁酸的枯草芽孢杆菌及其构建方法和应用
EP21179731.1 A Butyric Acid-producing Bacillus subtilis Strain, Method of Construction and Application Thereof
ZL201910711603. 5抗CD47纳米抗体突变体及其应用
ZL202010859938. 4一种包含人参提取物和益生菌的微生态制剂及其制备方法和应用
CN106350497B一种胰蛋白酶及其制备方法与应用
ZL201210465441.X 针对乏氧诱导因子-1a的纳米抗体及其编码序列
ZL201310293868.0 一种萤火虫荧光素酶及其编码基因及获取方法
ZL201310318276.X 靶向性重组PF4及其表达系统
ZL201520121594.1 乳腺癌早期预报家庭三联卡胶体金试剂盒
ZL201510665921.4 一种突变型Sus scrofa猪源胰蛋白酶及其编码基因及获取方法和应用
ZL201510176123.5 靶向性重组PF4及其表达系统
CN107312723 B 一种高产cAMP的酵母菌株及其应用
ZL2016800817306 一种高产cAMP的酵母菌株及其应用
CN105199974 B 一种分泌表达β-葡萄糖苷酶的重组酿酒酵母工业菌株及应用
CN101974547 B 含FLP的pBBR1MCS-2重组质粒及运动发酵单胞菌基因组DNA修饰的方法
CN102154344 B 编码β-葡萄糖苷酶的基因及重组表达载体及重组酿酒酵母表达菌株及应用
CN102080097 B 运动发酵单胞菌的电穿孔遗传操作方法
合著:
《实用病毒学》,天津科技翻译出版公司1999年12月出版
《现代糖尿病学》,天津科学技术出版社2000年7月出版
《生物化学》,高等教育出版社2010年2月出版
在学博士
在学硕士
学生荣誉墙
招生信息
天津大学研究生院招生办公室
文件上传中...